Dihydropyridine receptor blockers and skeletal muscle metabolism.
Thompson
C H
CH
Macaulay
V M
VM
O'Byrne
K J
KJ
Kemp
G J
GJ
Talbot
D C
DC
Harris
A L
AL
Radda
G K
GK
D000255:Adenosine Triphosphate / Q000096:biosynthesis; D000818:Animals; D002121:Calcium Channel Blockers / Q000494:pharmacology*; D015220:Calcium Channels / Q000187:drug effects*; D020746:Calcium Channels, L-Type; D002417:Cattle; D006801:Humans; D009682:Magnetic Resonance Spectroscopy; D008297:Male; D009119:Muscle Contraction / Q000502:physiology; D009124:Muscle Proteins / Q000096:biosynthesis; D018482:Muscle, Skeletal / Q000378:metabolism*; D009543:Nifedipine / Q000494:pharmacology*; D010101:Oxygen Consumption; D010725:Phosphocreatine / Q000096:biosynthesis; D051381:Rats; D017208:Rats, Wistar
D002121:Calcium Channel Blockers; D015220:Calcium Channels; D020746:Calcium Channels, L-Type; D009124:Muscle Proteins; D010725:Phosphocreatine; D000255:Adenosine Triphosphate; D009543:Nifedipine